Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients - 13/01/18
Doi : 10.1016/j.jaad.2017.10.043
Lucy Y. Liu, BA a, Brittany G. Craiglow, MD b, Brett A. King, MD, PhD b, ⁎ 
a Yale University School of Medicine, New Haven, Connecticut
b Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut
∗Reprint requests: Brett A. King, MD, PhD, Department of Dermatology, Yale University School of Medicine, PO Box 208059, New Haven, CT 06520.Department of DermatologyYale University School of MedicinePO Box 208059New HavenCT06520
| Funding sources: Dr Liu received funding support from the Yale University Medical Student Research Fellowship. Dr King received funding support from The Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research. |
|
| Conflicts of interest: Dr King has served on advisory boards or as consultant for Aclaris Therapeutics Inc, Celgene, Concert Pharmaceuticals Inc, Eli Lilly and Company, Pfizer Inc, Regeneron Pharmaceuticals, and Roivant Sciences Ltd. Other authors have no conflicts of interest to report. |
© 2017
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 78 - N° 2
P. 403 - février 2018 Retour au numéro
Article précédent
- Hidradenitis suppurativa and diabetes mellitus: A systematic review and meta-analysis
- Thanh-Lan Bui, Catalina Silva-Hirschberg, Josefina Torres, April W. Armstrong
- Epidemiology of staphylococcal scalded skin syndrome in the United States: A cross-sectional study, 2010-2014
- Justin D. Arnold, Shelby N. Hoek, A. Yasmine Kirkorian
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?